Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.22 Average Price Target from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average rating of “Hold” from the twenty ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $122.83.

Several equities research analysts recently commented on ZBH shares. BTIG Research dropped their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Wolfe Research started coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. Barclays lowered their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st.

Zimmer Biomet Price Performance

ZBH opened at $106.74 on Wednesday. Zimmer Biomet has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a 50 day moving average of $107.65 and a two-hundred day moving average of $108.82. The company has a market cap of $21.25 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the prior year, the company earned $1.65 EPS. The firm’s revenue was up 4.1% on a year-over-year basis. On average, analysts expect that Zimmer Biomet will post 7.99 earnings per share for the current year.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently bought and sold shares of ZBH. Dunhill Financial LLC raised its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth approximately $31,000. Family Firm Inc. acquired a new stake in shares of Zimmer Biomet in the 2nd quarter worth approximately $33,000. Finally, Brooklyn Investment Group bought a new stake in Zimmer Biomet during the third quarter worth approximately $35,000. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.